While we tend to view signature-negative and signature-positive patients as close variants of the same tumor subtype (e.g. HER2+:ERα−), they may represent different cancer subtypes that conventional immunohistochemistry with limited markers or microarray profiling (e.g. PAM50) fail to distinguish. This evidence concerns the gene ERBB2 and neoplasm.